project id: TCGA-BLCA; case submitter id: TCGA-FD-A3B4; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 8.5; age at index: 55; days to birth: -20379; days to death: 510; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Dead; year of birth: 1956; age at diagnosis: 20379; ajcc clinical t: T2; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T4a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 477.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: No; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: yes; alcohol history: Not Reported; cigarettes per day: 1.643835616438356; pack years smoked: 30.0; is ffpe: false; composition: Not Reported; days to collection: 141; days to sample procurement: 0; initial weight: 310.0; portion submitter id: TCGA-FD-A3B4-01A-12; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 10.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 35.0; percent tumor cells: 55.0; percent tumor nuclei: 80.0;